Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113328 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT06113328 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 169 participants.
The verdict
NCT06113328, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
Interventions
- DRUG Placebo
- BIOLOGICAL MK-6194
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06113328
The ClinicalTrials.gov registry entry for NCT06113328 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06113328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06113328 about?
NCT06113328 is a clinical study titled "A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)". Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on thei...
What is the current status of trial NCT06113328?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2023-11-27. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06113328?
The interventions under investigation include: Placebo (DRUG), MK-6194 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06113328?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.